Table 4.

Risk of invasive epithelial ovarian cancer associated with exclusive use of ET, EPT, CC-EPT hormone therapy

ET
EPT
CC-EPT
Controls, nInvasive cases, nOR* (95% CI)Controls, nInvasive cases, nOR* (95% CI)Controls, nInvasive cases, nOR* (95% CI)
Never used6142991.06142991.06142991.0
Ever167941.3 (0.9-1.8)3221270.8 (0.6-1.0)215750.7 (0.5-1.0)
Duration of use
    <60 mo67250.8 (0.5-1.4)131390.6 (0.4-0.8)88240.5 (0.3-0.8)
    60-119 mo26171.4 (0.7-2.6)83411.0 (0.6-1.5)61280.9 (0.5-1.5)
    120+ mo74521.7 (1.1-2.7)108470.9 (0.6-1.4)66230.8 (0.4-1.3)
Recency of use
    Current84491.3 (0.9-2.0)123661.0 (0.7-1.5)82411.0 (0.6-1.5)
    Former83451.2 (0.8-1.9)199610.6 (0.4-0.9)133340.5 (0.3-0.8)
        Recently quit (6-35 mo ago)27181.7 (0.9-3.2)95340.7 (0.4-1.1)69220.6 (0.4-1.0)
        Quit ≥3 y ago (36+ mo)56271.0 (0.6-1.7)104270.5 (0.3-0.8)64120.4 (0.2-0.7)
Duration of use
    Among current users
        <60 mo1960.6 (0.2-1.6)38170.9 (0.5-1.6)26120.9 (0.4-1.8)
        60+ mo65431.6 (1.0-2.5)85491.1 (0.7-1.7)56291.0 (0.6-1.7)
    Among former users
        <60 mo48190.9 (0.5-1.6)93220.4 (0.3-0.7)62120.4 (0.2-0.7)
        60+ mo35261.7 (1.0-3.1)106390.8 (0.5-1.2)71220.6 (0.4-1.1)
  • * Odds ratios adjusted for age, county of residence, year of diagnosis/reference date, number of full-term pregnancies, and duration of hormonal contraception.